ENYO PHARMA ANNOUNCES NEW CFO AND PROVIDES CLINICAL PIPELINE UPDATE
Lyon, France, September 19th, 2019 – Â鶹Æƽâ°æ, a private clinical stage biotechnology company developing innovative drug candidates, today announced the appointment of Jonathan Lieber as Chief Financial Officer. Â鶹Æƽâ°æ also provided a pipeline update today with a focus on EYP001 (Vonafexor, proposed INN), the Company’s FXR agonist that is currently in Phase II clinical development in both Hepatitis B (HBV) and Nonalcoholic Steatohepatitis (NASH).
Read next in 'Press releases'
- Â鶹Æƽâ°æ announces completion and topline data from Phase 2 ALPESTRIA-1 clinical study in Alport syndrome demonstrating Vonafexor reverses kidney function decline and has sustained therapeutic benefit
- Â鶹Æƽâ°æ annonce l’obtention des résultats finaux de l’étude clinique de Phase 2 ALPESTRIA‑1 dans le syndrome d’Alport, confirmant la capacité du vonafexor à inverser la trajectoire du déclin rénal et à démontrer un effet thérapeutique durable
- Â鶹Æƽâ°æ annonce la finalisation de son financement de série C avec Vesalius Biocapital et la poursuite de son étude clinique de phase 2 ALPESTRIA-1
- Â鶹Æƽâ°æ announces completion of Series C financing with Vesalius Biocapital and continued progress of its ALPESTRIA-1 clinical Phase 2 study in Alport syndrome patients
- Â鶹Æƽâ°æ announces a €39 million Series C financing and FDA clearance to advance Vonafexor in a Phase 2 clinical trial for patients with Alport syndrome
